TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
TriLink Solidifies IP Position with Awarded Patents for CleanCap Technology
TriLink Solidifies IP Position with Awarded Patents for CleanCap
TriLink BioTechnologies, a unit of Maravai LifeSciences, said it plans to expand its mRNA manufacturing operations to meet growing demand from late-stage drug developers.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analog
With the introduction of the CleanCap M6 technology, legacy capping methods like enzymatic and ARCA may be a thing of the past, according to the company. By combining the modification of 3’OMe on the m7-Guanosine and the additional methyl modification on the +1 Adenosine, the CleanCap M6 analog is expected to improve mRNA potency with the highest protein expression of any CleanCap analog yet.
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster.
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, has appointed Jeff Whitmore as chief commercial officer (CCO).
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate (N1me?TP), a modified nucleoside-triphosphate (NTP) essential for mRNA manufacturing. This new product extension leverages TriLink’s quality systems and GMP capabilities, including cleanroom manufacturing, expanded analytical testing, and process verification.